MarketPulse

Pivot to Growth

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva Gains Biosimilar Momentum With FDA Approval, Dual Regulatory Filings

Teva wins FDA approval for PONLIMSI biosimilar and dual regulatory filing acceptance for omalizumab biosimilar, advancing its 'Pivot to Growth' strategy.
AMGNNVSTEVAFDA approvalregulatory filing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva, Blackstone Life Sciences Team Up on $400M Deal for GI Drug duvakitug

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.
SNYTEVAmonoclonal antibodyclinical development